Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Crowe HM, Wesselink AK, Wise LA, Jick SS, Rothman KJ, Mikkelsen EM, Sorensen HT, Hatch EE. Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study. J. Headache Pain. 2022 Dec 20;23(1):162. doi: 10.1186/s10194-022-01533-6
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24
Brubaker L, Richter HE, Barber MD, Hsu Y, Rahn DD, Menefee S, Visco A, Spino C, Martin S, Meikle SF. Pelvic floor disorders clinical trials: participant recruitment and retention. Int Urogynecol J. 2013 Jan 1;24(1):73-9.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.